In this trial, patients with node-positive or high-risk node-negative (HR negative and tumor size >2cm) HER2-positive breast cancer were randomly assigned to anthracycline chemotherapy followed by trastuzumab and a taxane plus pertuzumab or anthracycline chemotherapy followed by T-DM1 plus pertuzumab. Here, ERBB2 is linked to breast carcinoma.